References
- 1. Apperley J, Carreras E, Gluckman E, Masszi T. The EBMT Handbook Haematopoietic Stem Cell Transplantation. 6th Revised Edition. 2012:317-326
- 2. Tsimberidou AM, Stavroyianni N, Viniou N. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer. 2003;97(7):1721-1731.
- 3. Büchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006; 24(16):2480-2489.
- 4. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood. 1997;90(8):2978-2986.
- 5. Isidori A, Bonifazi F, Visani G, et al. Autologous stem cell transplantation for acute myeloid patients in first complete remission: a 10-year follow-up study of 118 patients. Haematologica. 2005;90:139-140.
- 6. Suciu S, Mandelli F, de Witte T, et al. EORTC and GINEMA Leukemia Groups- Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia(AML) in first comlete remission(CR1): an intention-to-treat analysis of EORTC/GIMEMA AML-10 trial. Blood. 2003;102:1232-1240.
- 7. Wang J, Ouyang J, Zhou R, et al. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol. 2010;124(2):61-71.
- 8. Gordon MY, Blackett NM, Lewis JL, et al. Evidence for a mechanism that can provide both short-term and longterm haemopoetic repopulation by a seemingly uniform population of primitive human haemopoetic precursor cells. Leukemia. 1995;9:1252-6.
- 9. Villaon L, Odriozola J, Larana JG, et al. Autologous peripheral blood progenitor cell transplantation with <2x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment. Hematol J. 2000;1: 374-81.
- 10. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011;118(23):6037-42.
- 11. Ferrara F. Renaissance of autologous stem cell transplantation for AML? The Lancet Oncology. 2012;13(2):121-3.
- 12. Mehta J, Powles R, Sirhohi B, et al. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes. Blood. 2001;98(Suppl 1):716a.
- 13. Linker C. The role of autologous transplantation for acute myeloid leukemia in first and second remission. Best Pract Res Clin Haematol. 2007;20:77-84. Review.
- 14. Gorin NC, Labopin M, Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:3183-3188.
- 15. Thomas X, Suciu S, Rio B, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica. 2007;92:389-396.
- 16. Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia-new agents. Semin Hemat. 2006;43:96-106.